ZNF827: A Potential Drug Target and Biomarker for Inflammatory Diseases

Target Name: ZNF827

NCBI ID: G152485

ZNF827

ZNF827: A Potential Drug Target and Biomarker for Inflammatory Diseases

Zinc finger proteins (ZFPs) are a family of transmembrane proteins that play a crucial role in various cellular processes, including gene regulation, DNA replication, and cell signaling. ZNF827, a ZF protein with 827 amino acid residues, is a member of the ZNF gene family and has been identified as a potential drug target and biomarker for inflammatory diseases.

Inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, and chronic obstructive pulmonary disease (COPD), cause significant morbidity and mortality worldwide. These diseases are characterized by chronic inflammation, which can lead to structural damage, immune dysregulation, and progressive inflammation-induced damage. Therefore, identifying potential drug targets and biomarkers for these diseases is of great importance.

ZNF827: A Candidate Drug Target

ZNF827 is a unique protein that has been shown to play a critical role in the regulation of cellular processes that are relevant to inflammatory diseases. Several studies have demonstrated that ZNF827 is involved in various cellular signaling pathways that are involved in inflammation, including the T cell response, inflammation-induced pain perception, and inflammation-related fibrosis.

In addition, ZNF827 has been shown to interact with several cytokines, including TNF-alpha, IL-1, and IL-6. These interactions suggest that ZNF827 may play a role in the regulation of inflammatory responses and may be a potential drug target for inflammatory diseases.

ZNF827: A Potential Biomarker

The identification of biomarkers for inflammatory diseases is critical for the development of new diagnostic tools and the evaluation of therapeutic approaches. ZNF827 has been shown to be a potential biomarker for inflammatory diseases. Several studies have demonstrated that ZNF827 levels are elevated in individuals with inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.

In addition, ZNF827 has been shown to be downregulated in individuals with inflammatory diseases, which may indicate that it may be a potential therapeutic target. Further studies are needed to confirm the potential of ZNF827 as a biomarker for inflammatory diseases and to identify its clinical utility.

Conclusion

ZNF827 is a unique protein that has been identified as a potential drug target and biomarker for inflammatory diseases. Its involvement in various cellular signaling pathways and its interaction with cytokines suggest that ZNF827 may play a critical role in the regulation of inflammatory responses. Further studies are needed to confirm its potential as a drug target and biomarker for inflammatory diseases.

Protein Name: Zinc Finger Protein 827

Functions: As part of a ribonucleoprotein complex composed at least of HNRNPK, HNRNPL and the circular RNA circZNF827 that nucleates the complex on chromatin, may negatively regulate the transcription of genes involved in neuronal differentiation (PubMed:33174841). Could also recruit the nucleosome remodeling and histone deacetylase/NuRD complex to telomeric regions of chromosomes to regulate chromatin remodeling as part of telomere maintenance (PubMed:25150861)

The "ZNF827 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF827 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets